Welcome to our dedicated page for Lifemd SEC filings (Ticker: LFMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to LifeMD, Inc. (Nasdaq: LFMD) SEC filings, offering detailed insight into the company’s virtual primary care and pharmacy operations. As a U.S. public company, LifeMD files annual reports on Form 10‑K, quarterly reports on Form 10‑Q, and current reports on Form 8‑K, along with other required documents. These filings describe its telehealth platform, pharmacy and compounding pharmacy activities, clinical programs across more than 200 conditions, and its evolution into a pure-play virtual care and pharmacy business following the divestiture of its majority interest in WorkSimpli Software LLC.
Through LifeMD’s 10‑K and 10‑Q reports, readers can review segment information, revenue composition, operating expenses, and risk factors associated with telehealth, pharmacy services, regulatory compliance, and collaborations with pharmaceutical manufacturers. The company’s filings also discuss its 50-state affiliated medical group, proprietary digital care platform, and affiliated pharmacy infrastructure, providing context on how its virtual care model is structured.
LifeMD’s Form 8‑K filings capture material events such as the sale of its majority stake in WorkSimpli, the establishment of a senior secured revolving credit facility with Citizens Bank, N.A., rescheduling of earnings releases, and the announcement of quarterly financial results. These current reports may also include press releases as exhibits, giving additional narrative detail on strategic transactions, capital structure decisions, and operational milestones.
The company has also filed a Form 12b‑25 (NT 10‑Q) to notify the SEC of a late quarterly filing due to the need for additional time to correct errors related to over-recognition of revenue in prior periods. In that notification, LifeMD stated that the adjustments would not affect its cash flow or cash position and that it was evaluating potential impacts on internal control over financial reporting.
On Stock Titan, LifeMD’s filings are updated in near real time as they are posted to the SEC’s EDGAR system. AI-powered tools summarize lengthy documents such as 10‑K and 10‑Q reports, highlight key changes across periods, and surface important disclosures related to revenue recognition, segment reporting, credit facilities, preferred stock dividends, and significant transactions. Users can also review Form 4 and other ownership filings to track insider transactions and equity awards, with AI-generated explanations that clarify the nature of each transaction.
By combining raw SEC documents with AI-driven summaries and comparisons, this page helps investors, analysts, and researchers quickly understand LifeMD’s regulatory disclosures, financial reporting, and governance developments without manually parsing every filing.
Pisano Christopher A reported acquisition or exercise transactions in this Form 4 filing.
LifeMD, Inc. reported that Chief Marketing Officer Christopher A. Pisano received a grant of 200,000 shares of common stock in the form of restricted stock units on March 30, 2026. The award carries no purchase price.
According to the vesting terms, 50,000 units vest on the grant date, and an additional 50,000 units also vest on the grant dateMarch 30, 2027. A further 50,000 units vest on March 30, 2027, with the remaining units vesting on March 30, 2028, aligning the compensation with continued service at the company.
LifeMD, Inc. executive Christopher A. Pisano, the company’s Chief Marketing Officer, filed an initial Form 3 as a reporting person. The filing lists no transactions or holdings, serving as a baseline disclosure of his status as an officer subject to insider reporting rules.
LifeMD, Inc. filed an initial insider ownership report on SEC Form 3 for Atul Kavthekar, who serves as Chief Financial Officer. The filing identifies him as a reporting person but shows no buy, sell, exercise, gift, tax-withholding, or other transactions, with all transaction counts and share totals at zero in this excerpt.
LifeMD, Inc. announced a planned Chief Financial Officer transition, with current CFO Marc Benathen departing to pursue a new opportunity and remaining through March 31, 2026 to support an orderly handover. He will then provide transition advisory services for six to twelve months for a $38,117 monthly fee and receive COBRA reimbursement through no later than April 1, 2027, while forfeiting any RSUs unvested as of March 31, 2026.
The company appointed Atul Kavthekar as its new CFO effective March 16, 2026, with a base salary of $500,000 and an annual performance bonus targeted at 50% of base salary. As a material employment inducement, he will receive 675,000 RSUs, split evenly between time-based vesting over three years and performance-based vesting tied to company targets.
LifeMD also expanded its leadership team by promoting Chris Pisano to Chief Marketing Officer and Jessica Friedeman to Chief Business Officer, reflecting a broader effort to align finance, marketing, and business development with the company’s next phase of growth.
LifeMD, Inc. reports its 2025 annual results and details its evolution into a pure-play virtual care and pharmacy company. Revenue reached $194.1 million in 2025, up 25% from 2024, while net loss from continuing operations narrowed to $10.2 million from $23.2 million.
As of December 31, 2025, LifeMD served about 328,000 active patient subscribers, with roughly 95% of revenue from recurring subscriptions. The company expanded its vertically integrated telehealth platform, opened and enhanced a wholly owned pharmacy, and sold its majority interest in WorkSimpli, which is treated as discontinued operations.
LifeMD highlights growth in weight management, women’s health, behavioral health, and men’s health brands, supported by AI-enabled systems and a 50‑state provider network. It also emphasizes extensive regulatory, data privacy, AI, and healthcare fraud and abuse compliance risks that could materially affect future performance.
LifeMD, Inc. reported strong 2025 growth, with full-year revenue up 25% to $194.1 million and adjusted EBITDA up 309% to $15.3 million. Fourth-quarter revenue rose 4% to $46.9 million, while adjusted EBITDA increased to $4.8 million, reflecting an 87% gross margin.
The business from continuing operations still posted a 2025 GAAP net loss of $10.2 million, but total net income reached $15.6 million including discontinued operations. LifeMD ended 2025 with $36.8 million in cash and no debt, supporting investment in GLP-1 weight management, Wegovy launches, and expanding women’s health offerings.
For 2026, LifeMD guides to revenue of $220–$230 million and adjusted EBITDA of $12–$17 million, with annualized run-rate revenue expected to exceed $250 million and run-rate adjusted EBITDA to exceed $25 million by Q4 2026.
LifeMD, Inc. entered into a Credit Agreement with Citizens Bank providing a senior secured revolving credit facility of up to $30 million to support potential corporate development and shareholder value initiatives.
The facility may be increased by up to an additional $20 million and matures on January 2, 2029. Interest is variable, based on either Term SOFR plus a margin of 1.50%–2.25% or an Alternate Base Rate plus a margin of 0.50%–1.25%, with a commitment fee of 0.225%–0.30% on unused amounts, all tied to the Consolidated Leverage Ratio.
Key financial covenants require a Consolidated Leverage Ratio at or below 2.50 to 1.00 and a Consolidated Interest Coverage Ratio of at least 3.00 to 1.00, beginning with the quarter ending March 31, 2026. LifeMD had not drawn any funds under the facility as of the January 2, 2026 closing.
LifeMD, Inc. reported that its Chief Marketing Officer, Jessica Friedeman, sold 15,000 shares of common stock on 12/09/2025 at a weighted average price of $3.6105 per share. The sale was executed through multiple transactions at prices ranging from $3.585 to $3.645.
Following this transaction, she beneficially owns 205,000 shares of LifeMD common stock, held directly. This disclosure describes a personal stock transaction by a senior executive and does not itself indicate any change in LifeMD’s business operations or financial results.
LifeMD, Inc. reported stronger Q3 2025 results, with total revenue rising to $60.2 million from $53.3 million a year earlier, driven by growth in telehealth and steady WorkSimpli software subscriptions. For the first nine months of 2025, revenue reached $187.0 million, up from $149.3 million in the prior-year period, while the operating loss narrowed sharply to $1.4 million from $14.4 million.
Net loss attributable to common stockholders improved to $4.6 million in the quarter and $7.9 million year-to-date, compared with $5.4 million and $18.8 million in the prior-year periods, despite ongoing preferred dividends of $2.3 million for the nine months. LifeMD generated $11.6 million of cash from operations year-to-date, repaid its remaining $14.0 million Avenue credit facility, and ended September 30, 2025 with $23.8 million in cash and positive stockholders’ equity of $3.4 million. Management states that existing cash should fund planned operations and capital needs for at least the next 12 months.